Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

To Date: 01.10.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015– Acquisition/Purchase of Immovable Property Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Exchange that Telangana Industrial Infrastructure Corporation Limited (TGIIC) has issued the final allotment letter for allotment of Plot No. UDL-1, admeasuring 36,421 Sq. Mtrs., situated at UDL-Aroor, Sangareddy District, Telangana, for a total consideration of Rs.6,75,24,534/- (Rupees Six Crore Seventy-Five Lakh Twenty-Four Thousand Five Hundred and Thirty-Four Only). The salient details of the acquisition are as follows: Particulars Details Nature of transaction Purchase of Land Name of the Authority Telangana Industrial Infrastructure Corporation Limited (TGIIC) Nature of Transaction Final allotment of land Location & area of land Plot No(s).UDL-1 measuring 36421 Sq. Mts of land situated at UDL-Aroor, Sangareddy District Date of final allotment letter 01st October, 2026 Consideration Rs. 6,75,24,534/- (Rupees Six Croes Seventy-Five Lakhs Twenty-Four Thousand Five Hundred and Thirty-Four Only) Strategic rationale The acquisition has been undertaken with a view to support the Company's business operations / facilitate future expansion, establish additional infrastructure to meet the Company's long-term strategic requirements. The acquisition is expected to enhance the Company's operational capabilities and provide adequate infrastructure for its anticipated business growth. The value of the aforesaid transaction exceeds the materiality threshold prescribed under Regulation 30(4) of the SEBI LODR Regulations and, accordingly, the transaction is being disclosed to the Stock Exchanges. This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Mamilla Whole-time Director (DIN: 01998852)